| P50 | author | Benjamin D. Singer | Q42382392 |
| P2093 | author name string | Landon S King | |
| | Franco R D'Alessio | |
| P2860 | cites work | Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 |
| | Human T regulatory cell therapy: take a billion or so and call me in the morning | Q24656069 |
| | Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 |
| | Gene transfer in humans using a conditionally replicating lentiviral vector | Q24675343 |
| | T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development | Q85350477 |
| | Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis | Q85735927 |
| | Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies | Q27028025 |
| | Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 |
| | Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 |
| | Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 |
| | Use of epigenetic modification to induce FOXP3 expression in naïve T cells | Q28249415 |
| | Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells | Q28289781 |
| | Multiple immuno-regulatory defects in type-1 diabetes | Q28344695 |
| | Regulatory T cell lineage specification by the forkhead transcription factor foxp3 | Q28510328 |
| | Mechanisms of foxp3+ T regulatory cell-mediated suppression | Q29615842 |
| | The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 |
| | CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 |
| | Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 |
| | Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis | Q30437306 |
| | Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation | Q33367565 |
| | Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia | Q33629928 |
| | Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset | Q33999106 |
| | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab | Q34026630 |
| | Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. | Q34032006 |
| | A Disquisition on Suppressor T Cells | Q34051239 |
| | In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells | Q34089068 |
| | Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics | Q34144161 |
| | Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation | Q34162461 |
| | Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis | Q34311395 |
| | Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance | Q34448410 |
| | Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. | Q34529123 |
| | Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells | Q34548321 |
| | Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. | Q34553677 |
| | Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease | Q34556560 |
| | All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation | Q34580976 |
| | CTLA-4: a key regulatory point in the control of autoimmune disease | Q34593985 |
| | Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay | Q34640983 |
| | CD28 superagonists: what makes the difference in humans? | Q34656318 |
| | Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. | Q37208910 |
| | Itch expression by Treg cells controls Th2 inflammatory responses. | Q37259247 |
| | In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression | Q37273329 |
| | Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | Q37312884 |
| | CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury | Q37363024 |
| | Epigenetic mechanisms of regulation of Foxp3 expression | Q37412329 |
| | Acute graft-versus-host disease: from the bench to the bedside | Q37420496 |
| | Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease | Q37458586 |
| | Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? | Q37493607 |
| | Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. | Q37599553 |
| | Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy | Q37603816 |
| | Functional regulatory T cells and allergen immunotherapy. | Q37790956 |
| | Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. | Q37908437 |
| | Tregs: application for solid-organ transplantation | Q37964990 |
| | HDAC inhibitor therapy in autoimmunity and transplantation. | Q37998320 |
| | Regulatory cells in allergen-specific immunotherapy | Q38003474 |
| | Regulatory T-cell therapy for transplantation: how many cells do we need? | Q38025843 |
| | Translating tolerogenic therapies to the clinic - where do we stand? | Q38039091 |
| | Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. | Q38083439 |
| | Development and maintenance of regulatory T cells | Q38092234 |
| | Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. | Q38491611 |
| | CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. | Q39901615 |
| | Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. | Q40003509 |
| | Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production | Q40165347 |
| | A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells | Q40297048 |
| | Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. | Q40565739 |
| | Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. | Q40801370 |
| | Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor | Q41410840 |
| | Transplantation tolerance induced by antigen pretreatment and depleting anti‐CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response | Q41672486 |
| | An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. | Q41819445 |
| | CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta | Q42025024 |
| | The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 |
| | A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. | Q42827367 |
| | CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant | Q42907214 |
| | Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells | Q43003617 |
| | Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both. | Q43028008 |
| | Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery | Q43095588 |
| | Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin | Q43266964 |
| | Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease. | Q44114418 |
| | CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation | Q44408941 |
| | Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells | Q44950102 |
| | Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. | Q45299244 |
| | Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. | Q45922599 |
| | In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. | Q45961710 |
| | Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. | Q46005391 |
| | Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. | Q46223676 |
| | CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. | Q46763767 |
| | Deacetylase inhibition promotes the generation and function of regulatory T cells. | Q46961808 |
| | Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. | Q47828390 |
| | Regulatory T cells: recommendations to simplify the nomenclature. | Q48624465 |
| | Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. | Q48788015 |
| | Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. | Q50968365 |
| | Transplantation tolerance: memories that haunt us. | Q51005517 |
| | Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. | Q51765584 |
| | IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. | Q51998742 |
| | Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. | Q53522597 |
| | Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. | Q54193154 |
| | Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance | Q56904417 |
| | Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor–based drug regimens | Q60614966 |
| | IL-10 Is Required for Regulatory T Cells to Mediate Tolerance to Alloantigens In Vivo | Q60700622 |
| | Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus | Q61050853 |
| | Mechanism of induction of transplantation tolerance using donor antigen and anti-CD4 monoclonal antibody | Q68188003 |
| | Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy. A protocol with significant clinical potential | Q72086496 |
| | Modulation of the CD4 molecule is a major event in the induction of transplantation tolerance with anti-CD4 monoclonal antibodies | Q73278713 |
| | Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process | Q75224536 |
| | Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells | Q78806915 |
| | In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance | Q79143624 |
| | Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance | Q79468642 |
| | Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation | Q80754264 |
| | Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes | Q80967783 |
| | Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD | Q81014631 |
| | In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice | Q82335403 |
| | Regulatory T cells in cancer | Q84073243 |
| | First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells | Q84135263 |
| | The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation | Q34657284 |
| | Control of regulatory T cell lineage commitment and maintenance | Q34658594 |
| | Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates | Q34991139 |
| | Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. | Q34994485 |
| | TNF downmodulates the function of human CD4+CD25hi T-regulatory cells | Q35849817 |
| | The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. | Q35880886 |
| | Initiation of autoimmunity. | Q35931561 |
| | Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction | Q36135190 |
| | Organ transplantation--how much of the promise has been realized? | Q36152685 |
| | Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children | Q36181380 |
| | Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells | Q36228688 |
| | Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice | Q36228938 |
| | CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. | Q36229540 |
| | CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade | Q36369151 |
| | In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. | Q36370315 |
| | Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 |
| | Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? | Q36378864 |
| | Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells | Q36384673 |
| | Clinical application of expanded CD4+25+ cells | Q36386636 |
| | In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 |
| | Regulatory T-cell compartmentalization and trafficking | Q36421407 |
| | Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment | Q36539561 |
| | Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity | Q36551599 |
| | Human regulatory T cells and their role in autoimmune disease | Q36563532 |
| | Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells | Q36915913 |
| | CD28 costimulation is essential for human T regulatory expansion and function | Q36916914 |
| | Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis | Q37039571 |
| | Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 |
| | Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation | Q37065897 |
| | The Foxp3+ regulatory T cell: a jack of all trades, master of regulation | Q37088900 |
| | Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity | Q37100901 |
| | Identification of IL-17-producing FOXP3+ regulatory T cells in humans. | Q37122868 |
| | Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells | Q37180691 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 46 | |
| P577 | publication date | 2014-02-11 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Regulatory T cells as immunotherapy | |
| P478 | volume | 5 | |